Newsletter | November 17, 2026

11.17.26 -- What Europe's Draft Annex 22 Actually Asks Of Human Oversight Of AI

SPONSOR

Engineering confidence for cell and gene manufacturing.

3P innovation partners with cell and gene therapy developers, manufacturers and CDMOs to reduce manufacturing risk, accelerate scale-up and bring transformative therapies to patients faster. Our portfolio of advanced aseptic fill-finish platforms delivers proven, scalable technology, while our custom automation capability provides bespoke systems for complex manufacturing challenges. As a trusted automation engineering partner, we combine platform expertise with specialist engineering capability to deliver reliable, scalable solutions for the next generation of therapies.

FOCUS ON MANUFACTURING

What Europe's Draft Annex 22 Actually Asks Of Human Oversight Of AI

The European Commission and the Pharmaceutical Inspection Co-operation Scheme (PIC/S) consulted on draft Annex 22, Artificial Intelligence. Here's what you should know.

The Hidden Complexity Behind Pharmaceutical Labeling Machine Procurement

What is actually behind the procurement of a pharmaceutical labeling machine, and how does the process work? Find out here what the path to your pharmaceutical labeling machine looks like.

Connection Technologies Enable Modular Single-Use Systems

Single-use systems are increasingly prevalent in biotechnology processes. Explore the benefits, challenges, and solutions presented by modular single-use systems.

5 Key Questions On Implementing Pharma 4.0 Solutions For Fill-Finish

Pharma 4.0™ leverages IoT, AI, and automation to enhance drug quality. Evaluate your fill-finish line readiness by considering five key questions on modularity, high-risk process automation, and data integration.

Reducing Gene Therapy Development Time With Scalable Platform Approaches

Discover how a platform approach to AAV manufacturing can reduce development time and cost, as well as how optimized processes enable reliable production and scalable implementation in bioreactors.

Why Smarter Cell Expansion Strategies Are Critical For Therapy Scaling

As cell therapy scales, success depends on more than clinical promise. Smarter expansion strategies, automation, and flexible manufacturing platforms are becoming critical for improving consistency.

Achieving Robust AAV Production Through Controlled Bioreactor Environments

Uncover how controlled bioreactor environments enable optimization of critical process parameters and support robust, scalable AAV production from development through manufacturing.

Cell Harvesting: A Strategic Lever In Allogeneic Therapy Production

Current cell harvest techniques in allogeneic manufacturing face limitations, including scalability issues and cell damage. Learn why a shift in approach is vital for high-quality, efficient production at scale.

The Advantages Of Off-The-Shelf GMP iPSCs With A DMF

See how off-the-shelf, GMP-grade iPSC lines with a Drug Master File (DMF) can accelerate cell therapy development, streamline regulatory approval, and reduce time and cost to clinic.

Sensitive Viral Safety Testing For Adventitious Virus Detection

Examine a modern approach to adventitious virus detection that shows how targeted sequencing can achieve sensitive, comprehensive viral safety testing aligned with ICH MAP, RAP, and HAP expectations.

Simplifying Adenoviral Purification For Scalable Manufacturing

As vector design advances, downstream purification limits adenoviral manufacturing. A membrane-integrated hybrid train reduces product loss and process complexity at scale.

An Adaptable, Intelligent Centerpiece For Customizable Manufacturing

Data from a CAR T cell manufacturing case study challenges the assumption that automated cell processing platforms and third-party expansion technologies are inherently incompatible.

Capsules Versus Hollow Fibers For Ultrafiltration/Diafiltration (UF/DF)

Explore the performance evaluation of a first-of-its-kind spiral-wound TFF filter versus hollow fibers for UF/DF of viral vectors and the impact of either filter type on a TFF process.

MANUFACTURING SOLUTIONS

•

Productive Pipetting From 1 To 384 Channels - INTEGRA Biosciences

•

Expression Medium For High-Density Growth - Cytiva

•

Automate Your Fill/Finish Process For Precision - Terumo BCT

•

All-In-One Fully Automated Cell Therapy Development & Production Systems - CellBri

•

Closed System Cell Culture Flasks - Corning Life Sciences

•

Microbiological Cooled Incubator - PHC Corporation of North America

•

LVV Production System With Plasmid-Free Capability - Asimov

Connect With Cell & Gene: